Date:11/28/2012

ent may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

 Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersCindy McGee, Vice President

David Schull, PresidentInvestor Relations & Alliance Management

david.schull@russopartnersllc.comcmcgee@arenapharm.com

858.717.2310858.453.7200, ext. 1479 www.arenapharm.com  

'/>"/>

SOURCE Arena Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference
2. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
4. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
5. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
6. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
7. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
9. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
10. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
11. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs